NeoGenomics, a network of clinical laboratories, agreed to acquire Inivata, a biotechnology company, from Schroder, a closed-ended investment company, or $390m. "We are exercising our option to purchase Inivata eight months ahead of plan at what we believe is an attractive value in today's M&A marketplace for liquid biopsy companies. We are delighted to welcome Inivata's world class team of liquid biopsy experts and talented employees to NeoGenomics," Mark Mallon, NeoGenomics CEO.